CROSSROADS STRATEGIES, LLC for GENENTECH, INC.
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
Issues related to pharmaceutical IP and supply chain.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JASON GLEASON | — |
| JOHN GREEN | — |
| STEWART HALL | — |
| SHAY MICHAEL HANCOCK | — |
| MATHEW LAPINSKI | — |
| HUNTER MOORHEAD | — |
| JASON BENJAMIN VAN PELT | — |
| TODD MATTHEW WEISS | — |
Taxation/Internal Revenue Code TAX
Implementation of Tax Cuts and Jobs Act (P.L.115-97).
| Lobbyist | Covered position, as disclosed |
|---|---|
| JASON GLEASON | — |
| JOHN GREEN | — |
| STEWART HALL | — |
| SHAY MICHAEL HANCOCK | — |
| MATHEW LAPINSKI | — |
| HUNTER MOORHEAD | — |
| JASON BENJAMIN VAN PELT | — |
| TODD MATTHEW WEISS | — |
Budget/Appropriations BUD
Issues related to appropriations and federal health programs; reimbursement and vial size issues; FY2022 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act; H.R.748, CARES Act (P.L.116-136) implementation; H.R.133, Consolidated Appropriations Act, 2021 (P.L.116-260) implementation; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2).
| Lobbyist | Covered position, as disclosed |
|---|---|
| JASON GLEASON | — |
| JOHN GREEN | — |
| STEWART HALL | — |
| SHAY MICHAEL HANCOCK | — |
| MATHEW LAPINSKI | — |
| HUNTER MOORHEAD | — |
| JASON BENJAMIN VAN PELT | — |
| TODD MATTHEW WEISS | — |
Copyright/Patent/Trademark CPT
Biopharmaceutical innovation and patent policy issues. Trademark legislative proposals. Bayh-Dole march-in rights policy issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JASON GLEASON | — |
| JOHN GREEN | — |
| STEWART HALL | — |
| SHAY MICHAEL HANCOCK | — |
| MATHEW LAPINSKI | — |
| HUNTER MOORHEAD | — |
| JASON BENJAMIN VAN PELT | — |
| TODD MATTHEW WEISS | — |
Health Issues HCR
Issues related to health care, the Food and Drug Administration (FDA), 340B Program, influenza, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, and education around COVID-19 therapies. Implementation of Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22). Executive Order on Access to Affordable Life-saving Medications (E.O.13937); Executive Order on Increasing Drug Importation to Lower Prices for American Patients (E.O.13938); Executive Order on Lowering Prices for Patients by Eliminating Kickbacks to Middlemen (E.O.13939); Executive Orders on Lowering Drug Prices by Putting America First (E.O.13947, E.O.13948); Executive Order on Combating Public Health Emergencies and Strengthening National Security by Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs Are Made in the United States (E.O.13944); Executive Order on An America-First Healthcare Plan (E.O.13951). S.909, The Prescription Drug Price Relief Act; S.908, The Medicare Drug Price Negotiation Act; S.920, The Affordable and Safe Prescription Drug Importation Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JASON GLEASON | — |
| JOHN GREEN | — |
| STEWART HALL | — |
| SHAY MICHAEL HANCOCK | — |
| MATHEW LAPINSKI | — |
| HUNTER MOORHEAD | — |
| JASON BENJAMIN VAN PELT | — |
| TODD MATTHEW WEISS | — |
Medicare/Medicaid MMM
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Proposed Part B IPI Demonstration Project; Drug Pricing; Medicaid rebates and AMP Cap; H.R.1319, American Rescue Plan Act of 2021 (P.L.117-2); H.R.1868, To prevent across-the-board direct spending cuts, and for other purposes.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JASON GLEASON | — |
| JOHN GREEN | — |
| STEWART HALL | — |
| SHAY MICHAEL HANCOCK | — |
| MATHEW LAPINSKI | — |
| HUNTER MOORHEAD | — |
| JASON BENJAMIN VAN PELT | — |
| TODD MATTHEW WEISS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.